GLPwatch
A Study to Evaluate the Effect of Ranolazine on Postprandial Glucagon in Subjects With Type 2 Diabetes.
NCT01843127 · Completed
Last updated 2026-05-28This clinical trial is testing the effect of the medication ranolazine on blood sugar hormone levels after a meal in adults with type 2 diabetes.
Status Completed The study has finished.
Phase Phase 1 Checks safety and dosing in a small group.
Type Interventional (clinical trial)
Design Randomized, single-blind treatment study
Participants 24 people
Who can join Ages 18–65 · all sexes
Timeline Started 2013-04 · est. completion 2013-09
Where 3 sites · United States
What this study is testing ClinicalTrials.gov NCT01843127 ↗
Description as written by the study sponsor.
To explore the mechanism of action of ranolazine as a potential treatment for type 2 diabetes mellitus (T2DM).
Treatments tested
- Ranolazine Drug
- Placebo Drug
- Exenatide Drug
| Main thing measured | Area under the concentration-time curve (AUC) of plasma glucagon during the standard meal test (SMT) |
|---|---|
| Sponsor | Gilead Sciences |
| Conditions studied | Type 2 Diabetes Mellitus |
| GLP-1 drugs | — |
Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT01843127 ↗